Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66726
- Registration Number
- NCT00869908
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1032
- Registration Number
- NCT00865397
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 987
- Registration Number
- NCT00856986
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom
Observational Study on Levemir® in Obese Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 580
- Registration Number
- NCT00849342
Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3421
- Registration Number
- NCT00842894
An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2155
- Registration Number
- NCT00842192
- Locations
- 🇵🇰
Novo Nordisk Investigational Site, Karachi, Pakistan
Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 65
- Registration Number
- NCT00841087
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18481
- Registration Number
- NCT00825643
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00806897
- Locations
- 🇱🇹
Novo Nordisk Investigational Site, Vilnius, Lithuania
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00795600
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.